Journal article icon

Journal article

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Abstract:

Background:
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This study evaluated the efficacy and safety of tofacitinib 5 mg twice daily monotherapy after methotrexate withdrawal.


Methods:
OPAL Balance was an open-label, long-term extension study of tofacitinib in patients with psoriatic arthritis who participated in the OPAL Broaden and OPAL Bey...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Subgroup:
Botnar Research Centre
Role:
Author
ORCID:
0000-0002-4756-663X
Expand authors...
Publisher:
Elsevier Publisher's website
Journal:
Lancet Rheumatology Journal website
Publication date:
2020-11-16
Acceptance date:
2020-08-24
DOI:
EISSN:
2665-9913
Pubs id:
1133215
Local pid:
pubs:1133215
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP